LYON, (FRANCE), June 7th, 2023, – Following the American Society of Clinical Oncology’s, Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow”, the company highlighted its international scientific committee.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
